CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...